Evigrade
Moderate

Amlodipine × tacrolimus

Calcium channel blockers (dihydropyridines)×Calcineurin inhibitor (immunosuppressant)

Mechanism

Tacrolimus and amlodipine are both CYP3A4 substrates competing for the enzyme. Tacrolimus plasma levels may rise.

Symptoms

Acute nephrotoxicity: rising creatinine and falling glomerular filtration rate. Tremor, headache, hypertension, hyperglycaemia, hyperkalaemia. In transplant patients: accelerated graft decline.

Management

The combination is acceptable in post-transplant patients with hypertension. Check tacrolimus trough (C0) 1 week after starting or changing amlodipine. Alternative: an ARB or α-blocker (no CYP3A4 dependence).

Check the full regimen, not just this pair

Opens the checker with these two drugs prefilled. Add the rest of the regimen and recompute additive risks.

Open checker

Sources

All interactions